Atticus Wealth Management’s GSK GSK Stock Holding History

Atticus Wealth Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-400	Closed	-$13.5K	–	527
2024 Q4	$13.5K	Hold	400	–	–	﹤0.01%	367
2024 Q3	$16.4K	Hold	400	–	–	0.01%	350
2024 Q2	$15.4K	Hold	400	–	–	0.01%	339
2024 Q1	$17.1K	Hold	400	–	–	0.01%	342
2023 Q4	$14.8K	Hold	400	–	–	0.01%	361
2023 Q3	$14.5K	Hold	400	–	–	0.01%	363
2023 Q2	$14.3K	Hold	400	–	–	0.01%	368
2023 Q1	$14.2K	Sell	400 -286	-42%	-$10K	0.01%	354
2022 Q4	$24.1K	Sell	686 -530	-44%	-$17.7K	0.01%	319
2022 Q3	$53K	Buy	1,216 +243	+25%	+$9.21K	0.03%	226
2022 Q2	$53K	Hold	973	–	–	0.02%	246
2022 Q1	$53K	Buy	973 +400	+70%	+$21.7K	0.02%	241
2021 Q4	$32K	Sell	573 -400	-41%	-$20.8K	0.01%	273
2021 Q3	$46K	Sell	973 -286	-23%	-$14.4K	0.02%	244
2021 Q2	$63K	Hold	1,259	–	–	0.03%	209
2021 Q1	$56K	Hold	1,259	–	–	0.03%	202
2020 Q4	$58K	Hold	1,259	–	–	0.03%	198
2020 Q3	$59K	Hold	1,259	–	–	0.04%	165
2020 Q2	$64K	Hold	1,259	–	–	0.04%	158
2020 Q1	$60K	Sell	1,259 -16	-1%	-$853	0.05%	160
2019 Q4	$75K	Buy	+1,275	New	+$70.9K	0.05%	150

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Atticus Wealth Management's GSK Position: Q1 2025 in Review

Atticus Wealth Management sold out of GSK (GSK) in Q1 2025, closing a stake of 400 shares — an estimated $13.5K sold.

Atticus Wealth Management first reported a position in GSK in Q4 2019 and held it in 21 quarters. The position peaked at $75K in Q4 2019. 857 funds tracked by Wall St. Rank hold GSK as of Q1 2025.

Atticus Wealth Management reported no remaining GSK position as of Q1 2025 after selling out during the quarter.
Atticus Wealth Management sold 400 GSK shares in Q1 2025, an estimated $13.5K.
Atticus Wealth Management first reported a position in GSK in Q4 2019 and held it in 21 quarters.
Atticus Wealth Management's GSK position peaked at $75K in Q4 2019.
857 funds tracked by Wall St. Rank held GSK as of Q1 2025.

Based on Atticus Wealth Management's 13F filing for Q1 2025, filed 22 Apr 2025.